Abstract

Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in December 2017. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.